Le Lézard
Classified in: Health
Subject: PER

Echolight announces new executive hires

SEATTLE, Nov. 25, 2020 /PRNewswire/ -- On the heels of its recent US launch, Echolight Medical announces the hiring of several industry heavyweights, not only in radiology but specifically in point-of-care service. Seattle-based Gina Raebel is VP of Marketing. Florida-based Alex Exposito is VP of Sales. Washington-based Bryan Vick is VP of Operations & Customer Service. Headshots available here.

"Echolight is focused on moving bone density measurement and monitoring to the point-of-care to treat patients faster, more accurately, and in a non-invasive way, without relying on costly and time-consuming trips to the radiology department," explained Raebel, who most recently worked with Fujifilm Sonosite as Senior Director, Global Marketing and has spent more than a decade bringing advanced medical imaging technologies to the point-of-care. "Echolight's portable EchoS allows health care professionals to quickly diagnose and monitor patients wherever they are being treated."

More than half of the U.S. population is impacted by osteoporosis and low bone mass. Increased screening is essential to reducing fracture rates and must be more accessible to both patients and their point-of-care providers. Echolight seeks to position primary care physicians and private health and wellness professionals as frontline providers of bone density screening and monitoring at their practices.

Exposito is working with thought-leading doctors, hospitals, universities, coaches, nutritionists and other early adopters across the country to introduce "technology that is going to transform the way we look at bone health," he says. Having begun his career as a sonographer, Exposito has nearly 30 years experience in the field, most recently as Director, Strategic Accounts with Hologic. With success leading national and international teams driving sales of new ultrasound systems, medical devices, and capital equipment, Exposito is accustomed to building sales organizations for  start-ups and for new product launches. "EchoS is poised to be the new standard for measuring bone density and assessing fracture risk."

Vick is a customer-focused technical support leader with nearly 25 years of medical device experience. He most recently served 16+ years with Fujifilm Sonosite where he oversaw worldwide technical support for an installed base in excess of 60,000 units. Vick was with TriPath Imaging for eight years - four in manufacturing, four in service. Vick also served for six years in the United States Navy as an electronics technician and nuclear reactor operator. Vick said, "It's fulfilling to work among such a highly qualified team, and with a medical device that we all believe will transform a facet of healthcare."

About EchoS: Portable, diagnostic, radiation-free bone health densitometer - a safe, accurate, and cost-effective medical device elevating bone health awareness and treatment to mainstream medical care. FDA-cleared, EchoS uses Radiofrequency Echographic Multi Spectrometry (R.E.M.S.) to measure Bone density and provides T-score, Z-score, and a qualitative assessment of bone microarchitecture, independent of bone density, to predict future fracture risk. All provided in minutes. Learn more at EcholightMedical.com.

Jesse Landis
813.846.3167 (cell)

SOURCE Echolight Medical

These press releases may also interest you

at 00:00
Surrey physician, Dr. Sachit Shah, of Beautiful Canadian Laser and Skincare Clinic, has been approved as the first doctor in B.C. to offer non-surgical facelifts using a newer, Health Canada approved thread material. "This is a very fast and...

22 jan 2021
The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine's efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of...

22 jan 2021
The Alisal Guest Ranch and Resort has partnered with biosafety company R-Zero, incorporating the company's hospital-grade UV-C technology into its disinfection protocols to ensure a safe reopening for guests and staff amid the COVID-19 pandemic. The...

22 jan 2021
The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals' LupkynisTM (voclosporin) as the first oral treatment developed specifically for adults with active...

22 jan 2021
For the second time in less than two months, the U.S. Food and Drug Administration (FDA) has approved a new medication to treat adults with lupus nephritis (lupus-related kidney disease) in combination with a background immunosuppressive therapy...

22 jan 2021
Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved LUPKYNISTM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult...

News published on 25 november 2020 at 10:03 and distributed by: